After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
PTGX belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Protagonist Therapeutics Inc is $2.23B. A total of 0.93 million shares were traded on the day, compared to an average of 623.65K shares.
In the most recent transaction, PATEL DINESH V PH D sold 5,359 shares of PTGX for 38.18 per share on Feb 19 ’25. After the transaction, the President and CEO now owns 540,260 company shares. In a previous transaction on Nov 27 ’24, MOLINA ARTURO MD sold 26,000 shares at 44.70 per share. PTGX shares that Chief Medical Officer owns now total 46,444.
Among the insiders who sold shares, MOLINA ARTURO MD disposed of 5,529 shares on Nov 26 ’24 at a per-share price of $45.60. This resulted in the Chief Medical Officer holding 46,444 shares of PTGX after the transaction. In another insider transaction, Gupta Suneel sold 103,437 shares at $46.04 per share on Nov 25 ’24. Company shares held by the Chief Development Officer now total 256,174.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, PTGX has a high of $48.89 and a low of $24.22.
As of this writing, PTGX has an earnings estimate of $0.28 per share for the current quarter. EPS was calculated based on a consensus of 6.0 estimates, with a high estimate of $1.87 per share and a lower estimate of -$0.58.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. PTGX’s latest balance sheet shows that the firm has $326.90M in Cash & Short Term Investments as of fiscal 2021. There were $5.86M in debt and $44.02M in liabilities at the time. Its Book Value Per Share was $11.06, while its Total Shareholder’s Equity was $300.02M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PTGX is Buy with a score of 4.80.
